Inorganic engineered nanoparticles and their impact on the immune response

Current Drug Metabolism

Volumn 10, Issue 8, 2009, Pages 895-904

  Sperling, Ralph A ^a   Casals, Eudald ^a   Comenge, Joan ^a,b   Bastús, Neus G ^a   Puntes, Victor F ^a,c  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b INTERNATIONAL IBERIAN NANOTECHNOLOGY LABORATORY   (Portugal)

^c INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

Author keywords

Biodegradation; Endocytosis; Immune system; Inflammation; Macrophages; Nanomaterials; Nanoparticles; Surface modification

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 12; MACROGOL; NANOPARTICLE; POLIOMYELITIS VACCINE; QUANTUM DOT; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR;

ARTICLE; ENDOCYTOSIS; IMMUNE RESPONSE; IMMUNOMODULATION; MACROPHAGE; PARTICLE SIZE; PHYSICAL CHEMISTRY; RETICULOENDOTHELIAL SYSTEM; SURFACE CHARGE;

EID: 74249122226     PISSN: 13892002     EISSN: None     Source Type: Journal    
DOI: 10.2174/138920009790274577     Document Type: Article

References (99)

1. Künzli, N.; Jerrett, M.; Mack, W. J.; Beckerman, B.; LaBree, L.; Gilliland, F.; Thomas, D.; Peters, J.; Hodis, H. N. Ambient air pollution and atherosclerosis in Los Angeles. Environ. Health Perspect., 2005, 113(2), 201-206.
2. Turvey, S. E.; Hawn, T. R. Towards subtlety: Understanding the role of Toll-like receptor signaling in susceptibility to human infections. Clin. Immunol., 2006, 120(1), 1-9.
3. Pfaller, T.; Puntes, V.; Casals, E.; Duschl, A.; Oostingh, G. In vitro investigation of immunomodulatory effects caused by engineered inorganic nanoparticles - the impact of experimental design and cell choice. Nanotoxicology, 2009, 3(1), 46-59.
4. Poland, C. A.; Duffin, R.; Kinloch, I.; Maynard, A.; Wallace, W. A. H.; Seaton, A.; Stone, V.; Brown, S.; Macnee, W.; Donaldson, K. Carbon nanotubes introduced into the abdominal cavity of mice show asbestos-like pathogenicity in a pilot study. Nat. Nanotechnol., 2008, 3(7), 423-428.
5. Krieg, A. M. Therapeutic potential of Toll-like receptor 9 activation. Nat. Rev. Drug Discov., 2006, 5(6), 471-484.
6. Nel, A. E.; Madler, L.; Velegol, D.; Xia, T.; Hoek, E. M. V.; Somasundaran, P.; Klaessig, F.; Castranova, V.; Thompson, M. Understanding biophysicochemical interactions at the nano-bio interface. Nat. Mater., 2009, 8(7), 543-557.
7. Sen, D.; Deerinck, T. J.; Ellisman, M. H.; Parker, I.; Cahalan, M. D. Quantum dots for tracking dendritic cells and priming an immune response in vitro and in vivo. PLoS ONE, 2008, 3(9), e3290.
8. Reddy, S. T.; Rehor, A.; Schmoekel, H. G.; Hubbell, J. A.; Swartz, M. A. In vivo targeting of dendritic cells in lymph nodes with poly(propylene sulfide) nanoparticles. J. Control. Release, 2006, 112(1), 26-34.
9. Nagayama, S.; Ogawara, K.; Fukuoka, Y.; Higaki, K.; Kimura, T. Time-dependent changes in opsonin amount associated on nanoparticles alter their hepatic uptake characteristics. Int. J. Pharm., 2007, 342(1-2), 215-221.
10. Park, J.; Joo, J.; Kwon, S. G.; Jang, Y.; Hyeon, T. Synthesis of monodisperse spherical nanocrystals. Angew. Chem. Int. Ed., 2007, 46(25), 4630-4660.
11. Casals, E.; Vazquez-Campos, S.; Bastús, N. G.; Puntes, V. Distribution and potential toxicity of engineered inorganic nanoparticles and carbon nanostructures in biological systems. TrAC-Trend. Anal. Chem., 2008, 27(8), 672-683.
12. Dobrovolskaia, M. A.; McNeil, S. E. Immunological properties of engineered nanomaterials. Nat. Nanotechnol., 2007, 2(8), 469-478.
13. Perrault, S. D.; Walkey, C.; Jennings, T.; Fischer, H. C.; Chan, W. C. W. Mediating tumor targeting efficiency of nanoparticles through design. Nano Lett., 2009, 9(5), 1909-1915.
14. Fang, C.; Shi, B.; Pei, Y.; Hong, M.; Wu, J.; Chen, H. In vivo tumor targeting of tumor necrosis factor-alpha-loaded stealth nanoparticles: effect of MePEG molecular weight and particle size. Eur. J. Pharm. Sci., 2006, 27(1), 27-36.
15. Kim, J. S.; Yoon, T.; Yu, K. N.; Kim, B. G.; Park, S. J.; Kim, H. W.; Lee, K. H.; Park, S. B.; Lee, J.; Cho, M. H. Toxicity and tissue distribution of magnetic nanoparticles in mice. Toxicol. Sci., 2006, 89(1), 338-347.
16. Chittimalla, C.; Zammut-Italiano, L.; Zuber, G.; Behr, J. Monomolecular DNA nanoparticles for intravenous delivery of genes. J. Am. Chem. Soc., 2005, 127(32), 11436-11441.
17. Podsiadlo, P.; Sinani, V. A.; Bahng, J. H.; Kam, N. W. S.; Lee, J.; Kotov, N. A. Gold nanoparticles enhance the anti-leukemia action of a 6-mercaptopurine chemotherapeutic agent. Langmuir, 2008, 24(2), 568-574.
18. Cuña, M.; Alonso-Sandel, M.; Remunan-Lopez, C.; Pivel, J. P.; Alonso-Lebrero, J. L.; Alonso, M. J. Development of phosphorylated glucomannan-coated chitosan nanoparticles as nanocarriers for protein delivery. J. Nanosci. Nanotechnol., 2006, 6(9-10), 2887-2895.
19. Xiang, S. D.; Scholzen, A.; Minigo, G.; David, C.; Apostolopoulos, V.; Mottram, P. L.; Plebanski, M. Pathogen recognition and development of particulate vaccines: Does size matter? Methods, 2006, 40(1), 1-9.
20. Reddy, S. T.; Van der Vlies, A. J.; Simeoni, E.; Angeli, V.; Randolph, G. J.; O'Neil, C. P.; Lee, L. K.; Swartz, M. A.; Hubbell, J. A. Exploiting lymphatic transport and complement activation in nanoparticle vaccines. Nat. Biotechnol., 2007, 25(10), 1159-1164.
21. van Zijverden, M.; Granum, B. Adjuvant activity of particulate pollutants in different mouse models. Toxicology, 2000, 152(1-3), 69-77.
22. Heffner, D. K. The cause of sarcoidosis: the Centurial enigma solved. Ann. Diagn. Pathol., 2007, 11(2), 142-152.
23. Veronese, F. M.; Harris, J. M. Introduction and overview of peptide and protein pegylation. Adv. Drug Deliv. Rev., 2002, 54(4), 453-456.
24. Veronese, F. M.; Harris, J. M. Peptide and protein PEGylation III: Advances in chemistry and clinical applications. Adv. Drug Deliv. Rev., 2008, 60(1), 1-2.
25. Kreppel, F.; Kochanek, S. Modification of adenovirus gene transfer vectors with synthetic polymers: a scientific review and technical guide. Mol. Ther., 2007, 16(1), 16-29.
26. Immordino, M. L.; Dosio, F.; Cattel, L. Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. Int. J. Nanomed., 2006, 1(3), 297-315.
27. Ballou, B.; Lagerholm, B. C.; Ernst, L. A.; Bruchez, M. P.; Waggoner, A. S. Noninvasive imaging of quantum dots in mice. Bioconjug. Chem., 2004, 15(1), 79-86.
28. Daou, T. J.; Li, L.; Reiss, P.; Josserand, V.; Texier, I. Effect of poly(ethylene glycol) length on the in vivo behavior of coated quantum dots. Langmuir, 2009, 25(5), 3040-3044.
29. Soo Choi, H.; Liu, W.; Misra, P.; Tanaka, E.; Zimmer, J. P.; Itty Ipe, B.; Bawendi, M. G.; Frangioni, J. V. Renal clearance of quantum dots. Nat. Biotechnol., 2007, 25(10), 1165-1170.
30. Yang, R. S. H.; Chang, L. W.; Wu, J.; Tsai, M.; Wang, H.; Kuo, Y.; Yeh, T.; Yang, C. S.; Lin, P. Persistent tissue kinetics and redistribution of nanoparticles, quantum dot 705, in mice: ICP-MS quantitative assessment. Environ. Health Perspect., 2007, 115(9), 1339-1343.
31. Owens III, D. E.; Peppas, N. A. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int. J. Pharm., 2006, 307(1), 93-102.
32. Kikkeri, R.; Lepenies, B.; Adibekian, A.; Laurino, P.; Seeberger, P. H. In Vitro Imaging and in Vivo Liver Targeting with Carbohydrate Capped Quantum Dots. J. Am. Chem. Soc., 2009, 131(6), 2110-2112.
33. Cheng, T.; Cheng, C.; Chen, B.; Tsao, D.; Chuang, K.; Hsiao, S.; Lin, Y.; Roffler, S. R. Monoclonal Antibody-Based Quantitation of Poly(ethylene glycol)-Derivatized Proteins, Liposomes, and Nanoparticles. Bioconjug. Chem., 2005, 16(5), 1225-1231.
34. Cho, W.; Cho, M.; Jeong, J.; Choi, M.; Cho, H.; Han, B. S.; Kim, S. H.; Kim, H. O.; Lim, Y. T.; Chung, B. H.; Jeong, J. Acute toxicity and pharmacokinetics of 13nm-sized PEG-coated gold nanoparticles. Toxicol. Appl. Pharmacol., 2009, 236(1), 16-24.
35. Peracchia, M. T.; Harnisch, S.; Pinto-Alphandary, H.; Gulik, A.; Dedieu, J. C.; Desmaële, D.; d'Angelo, J.; Müller, R. H.; Couvreur, P. Visualization of in vitro protein-rejecting properties of PEGylated stealth® polycyanoacrylate nanoparticles. Biomaterials, 1999, 20(14), 1269-1275.
36. Balakrishnan, B.; Kumar, D.; Yoshida, Y.; Jayakrishnan, A. Chemical modification of poly(vinyl chloride) resin using poly(ethylene glycol) to improve blood compatibility. Biomaterials, 2005, 26(17), 3495-3502.
37. Oyewumi, M. O.; Yokel, R. A.; Jay, M.; Coakley, T.; Mumper, R. J. Comparison of cell uptake, biodistribution and tumor retention of folate-coated and PEG-coated gadolinium nanoparticles in tumorbearing mice. J. Control. Release, 2004, 95(3), 613-626.
38. Koziara, J.; Oh, J.; Akers, W.; Ferraris, S.; Mumper, R. Blood compatibility of cetyl alcohol/polysorbate-based nanoparticles. Pharm. Res., 2005, 22(11), 1821-1828.
39. Bachmann, M.; Rohrer, U.; Kundig, T.; Bürki, K.; Hengartner, H.; Zinkernagel, R. The influence of antigen organization on B cell responsiveness. Science, 1993, 262(5138), 1448-1451.
40. Bastús, N. G.; Sánchez-Tilló, E.; Pujals, S.; Farrera, C.; Kogan, M. J.; Giralt, E.; Celada, A.; Lloberas, J.; Puntes, V. Peptides conjugated to gold nanoparticles induce macrophage activation. Mol. Immunol., 2009, 46(4), 743-748.
41. Bastús, N. G.; Sánchez-Tilló, E.; Pujals, S.; Farrera, C.; Lopez, C.; Giralt, E.; Celada, A.; Lloberas, J.; Puntes, V. Homogeneous conjugation of peptides onto gold nanoparticles enhances macrophage response. ACS Nano, 2009, 3(6), 1335-1344.
42. Ebbesen, P. DEAE-dextran and polybrene cation enhancement and dextran sulfate anion inhibition of immune cytolysis. J. Immunol., 1972, 109(6), 1296-1299.
43. Morgan, D.; Larvin, V.; Pearson, J. Biochemical characterisation of polycation-induced cytotoxicity to human vascular endothelial cells. J. Cell Sci., 1989, 94(3), 553-559.
44. Hoet, P. H. M.; Gilissen, L.; Nemery, B. Polyanions protect against the in vitro pulmonary toxicity of polycationic paint components associated with the ardystil syndrome. Toxicol. Appl. Pharmacol., 2001, 175(2), 184-190.
45. Hoshino, A.; Fujioka, K.; Oku, T.; Suga, M.; Sasaki, Y. F.; Ohta, T.; Yasuhara, M.; Suzuki, K.; Yamamoto, K. Physicochemical properties and cellular toxicity of nanocrystal quantum dots depend on their surface modification. Nano Lett., 2004, 4(11), 2163-2169.
46. Goodman, C. M.; McCusker, C. D.; Yilmaz, T.; Rotello, V. M. Toxicity of gold nanoparticles functionalized with cationic and anionic side chains. Bioconjug. Chem., 2004, 15(4), 897-900.
47. Balogh, L.; Nigavekar, S. S.; Nair, B. M.; Lesniak, W.; Zhang, C.; Sung, L. Y.; Kariapper, M. S.; El-Jawahri, A.; Llanes, M.; Bolton, B.; Mamou, F.; Tan, W.; Hutson, A.; Minc, L.; Khan, M. K. Significant effect of size on the in vivo biodistribution of gold composite nanodevices in mouse tumor models. Nanomedicine, 2007, 3(4), 281-296.
48. Tan, Y.; Li, S.; Pitt, B. R.; Huang, L. the inhibitory role of CpG immunostimulatory motifs in cationic lipid vector-mediated transgene expression in vivo. Hum. Gene Ther., 1999, 10(13), 2153.
49. Cui, Z.; Han, S.; Vangasseri, D. P.; Huang, L. Immunostimulation mechanism of LPD nanoparticle as a vaccine carrier. Mol. Pharm., 2005, 2(1), 22-28.
50. Gref, R.; Minamitake, Y.; Peracchia, M.; Trubetskoy, V.; Torchilin, V.; Langer, R. Biodegradable long-circulating polymeric nanospheres. Science, 1994, 263(5153), 1600-1603.
51. Jaiswal, J. K.; Mattoussi, H.; Mauro, J. M.; Simon, S. M. Longterm multiple color imaging of live cells using quantum dot bioconjugates. Nat. Biotechnol., 2003, 21(1), 47-51.
52. Wu, X.; Liu, H.; Liu, J.; Haley, K. N.; Treadway, J. A.; Larson, J. P.; Ge, N.; Peale, F.; Bruchez, M. P. Immunofluorescent labeling of cancer marker Her2 and other cellular targets with semiconductor quantum dots. Nat. Biotechnol., 2003, 21(1), 41-46.
53. Gao, X.; Cui, Y.; Levenson, R. M.; Chung, L. W. K.; Nie, S. In vivo cancer targeting and imaging with semiconductor quantum dots. Nat. Biotechol., 2004, 22(8), 969-976.
54. Ahrens, E.; M. Feili-Hariri; H. Xu; G. Genove; P. A. Morel Receptor-mediated endocytosis of iron-oxide particles provides efficient labeling of dendritic cells for in vivo MR imaging. Magn. Reson. Med., 2003, 49(6), 1006-1013.
55. Conner, S. D.; Schmid, S. L. Regulated portals of entry into the cell. Nature, 2003, 422(6927), 37-44.
56. Chithrani, B. D.; Chan, W. C. W. Elucidating the mechanism of cellular uptake and removal of protein-coated gold nanoparticles of different sizes and shapes. Nano Lett., 2007, 7(6), 1542-1550.
57. Taylor, P.; Martinez-Pomares, L.; Stacey, M.; Lin, H.; Brown, G.; Gordon, S. Macrophage Receptors and Immune Recognition. Annu. Rev. Immunol., 2005, 23(1), 901-944.
58. Sadauskas, E.; Danscher, G.; Stoltenberg, M.; Vogel, U.; Larsen, A.; Wallin, H. Protracted elimination of gold nanoparticles from mouse liver. Nanomedicine, 2009, 5(2), 162-169.
59. Kew, O.; Morris-Glasgow, V.; Landaverde, M.; Burns, C.; Shaw, J.; Garib, Z.; Andre, J.; Blackman, E.; Freeman, C. J.; Jorba, J.; Sutter, R.; Tambini, G.; Venczel, L.; Pedreira, C.; Laender, F.; Shimizu, H.; Yoneyama, T.; Miyamura, T.; van der Avoort, H.; Oberste, M. S.; Kilpatrick, D.; Cochi, S.; Pallansch, M.; de Quadros, C. Outbreak of poliomyelitis in hispaniola associated with circulating type 1 vaccine-derived poliovirus. Science, 2002, 296(5566), 356-359.
60. Greensfelder, L. Infectious diseases: Polio outbreak raises questions about vaccine. Science, 2000, 290(5498), 1867b-1869.
61. Bachmann, M. F.; Zinkernagel, R. M.; Oxenius, A. Cutting edge commentary: Immune responses in the absence of costimulation: Viruses know the trick. J. Immunol., 1998, 161(11), 5791-5794.
62. Banerjee, T.; Mitra, S.; Kumar Singh, A.; Kumar Sharma, R.; Maitra, A. Preparation, characterization and biodistribution of ultrafine chitosan nanoparticles. Int. J. Pharm., 2002, 243(1-2), 93-105.
63. Janes, K. A.; Calvo, P.; Alonso, M. J. Polysaccharide colloidal particles as delivery systems for macromolecules. Adv. Drug Deliv. Rev., 2001, 47(1), 83-97.
64. Chavany, C.; Saison-Behmoaras, T.; Doan, T. L.; Puisieux, F.; Couvreur, P.; Hélène, C. Adsorption of oligonucleotides onto polyisohexylcyanoacrylate nanoparticles protects them against nucleases and increases their cellular uptake. Pharm. Res., 1994, 11(9), 1370-1378.
65. Wolfrum, C.; Shi, S.; Jayaprakash, K. N.; Jayaraman, M.; Wang, G.; Pandey, R. K.; Rajeev, K. G.; Nakayama, T.; Charrise, K.; Ndungo, E. M.; Zimmermann, T.; Koteliansky, V.; Manoharan, M.; Stoffel, M. Mechanisms and optimization of in vivo delivery of lipophilic siRNAs. Nat. Biotechnol., 2007, 25(10), 1149-1157.
66. Abbas, A. Cellular and Molecular Immunology, 5th ed.; Saunders: Philadelphia, 2003.
67. Semmler-Behnke, M.; Kreyling, W. G.; Lipka, J.; Fertsch, S.; Wenk, A.; Takenaka, S.; Schmid, G.; Brandau, W. Biodistribution of 1.4- and 18-nm Gold Particles in Rats. Small, 2008, 4(12), 2108-2111.
68. Lee, J.; Salvati, E.; Betts, F.; DiCarlo, E.; Doty, S.; Bullough, P. Size of metallic and polyethylene debris particles in failed cemented total hip replacements. J. Bone Joint Surg. Br., 1992, 74-B(3), 380-384.
69. Vonarbourg, A.; Passirani, C.; Saulnier, P.; Benoit, J. Parameters influencing the stealthiness of colloidal drug delivery systems. Biomaterials, 2006, 27(24), 4356-4373.
70. Roser, M.; Fischer, D.; Kissel, T. Surface-modified biodegradable albumin nano- and microspheres. II: effect of surface charges on in vitro phagocytosis and biodistribution in rats. Eur. J. Pharm. Biopharm., 1998, 46(3), 255-263.
71. Brash, J. L. In Proteins at Interfaces; ACS Symposium Series; American Chemical Society: Washington, DC, 1987; pp. 490-506.
72. Juliano, R. L. Factors affecting the clearance kinetics and tissue distribution of liposomes, microspheres and emulsions. Adv. Drug Deliv. Rev., 1988, 2(1), 31-54.
73. Stolnik, S.; Illum, L.; Davis, S. S. Long circulating microparticulate drug carriers. Adv. Drug Deliv. Rev., 1995, 16(2-3), 195-214.
74. Leroux, J.; Jaeghere, F. D.; Anner, B.; Doelker, E.; Gurny, R. An investigation on the role of plasma and serum opsonins on the evternalization of biodegradable poly(D,L-lactic acid) nanoparticles by human monocytes. Life Sci., 1995, 57(7), 695-703.
75. Leroux, J.; Allémann, E.; Jaeghere, F. D.; Doelker, E.; Gurny, R. Biodegradable nanoparticles - From sustained release formulations to improved site specific drug delivery. J. Control. Release, 1996, 39(2-3), 339-350.
76. Verma, A.; Uzun, O.; Hu, Y.; Hu, Y.; Han, H.; Watson, N.; Chen, S.; Irvine, D. J.; Stellacci, F. Surface-structure-regulated cellmembrane penetration by monolayer-protected nanoparticles. Nat. Mater., 2008, 7(7), 588-595.
77. Chambers, E.; Mitragotri, S. Long circulating nanoparticles via adhesion on red blood cells: mechanism and extended circulation. Exp. Biol. Med., 2007, 232(7), 958-966.
78. Gessner, A.; Waicz, R.; Lieske, A.; Paulke, B.; Mader, K.; Müller, R. H. Nanoparticles with decreasing surface hydrophobicities: influence on plasma protein adsorption. Int. J. Pharm., 2000, 196(2), 245-249.
79. Lück, M.; Pistel, K.; Li, Y.; Blunk, T.; Müller, R. H.; Kissel, T. Plasma protein adsorption on biodegradable microspheres consist ing of poly(-lactide-co-glycolide), poly(-lactide) or ABA triblock copolymers containing poly(oxyethylene): Influence of production method and polymer composition. J. Control. Release, 1998, 55(2-3), 107-120.
80. Cedervall, T.; Lynch, I.; Lindman, S.; Berggård, T.; Thulin, E.; Nilsson, H.; Dawson, K. A.; Linse, S. Understanding the nanoparticle-protein corona using methods to quantify exchange rates and affinities of proteins for nanoparticles. Proc. Natl. Acad. Sci. U.S.A., 2007, 104(7), 2050-2055.
81. Lundqvist, M.; Stigler, J.; Elia, G.; Lynch, I.; Cedervall, T.; Dawson, K. A. Nanoparticle size and surface properties determine the protein corona with possible implications for biological impacts. Proc. Natl. Acad. Sci. U.S.A., 2008, 105(38), 14265-14270.
82. Keogh, J. R.; Fredrik F. Velander; John W. Eaton Albumin-binding surfaces for implantable devices. J. Biomed. Mater. Res., 1992, 26(4), 441-456.
83. Buckton, G. In Interfacial Phenomena in Drug Delivery and Targeting; Drug Targeting and Delivery; CRC Press: Boca Raton (FL), 1995; Vol. 5, pp. 237-281.
84. Gradishar, W. J.; Tjulandin, S.; Davidson, N.; Shaw, H.; Desai, N.; Bhar, P.; Hawkins, M.; O'Shaughnessy, J. Superior Efficacy of Albumin-Bound Paclitaxel, ABI-007, Compared With Polyethylated Castor Oil-Based Paclitaxel in Women With Metastatic Breast Cancer: Results of a Phase III Trial. J. Clin. Oncol., 2005, 23(31), 7765-7767.
85. Larsen, A.; Kolind, K.; Pedersen, D.; Doering, P.; Pedersen, M.; Danscher, G.; Penkowa, M.; Stoltenberg, M. Gold ions bio-released from metallic gold particles reduce inflammation and apoptosis and increase the regenerative responses in focal brain injury. Histochem. Cell Biol., 2008, 130(4), 681-692.
86. Gutierrez, L.; Lázaro, F. J.; Abadía, A. R.; Romero, M. S.; Quintana, C.; Puerto Morales, M.; Patino, C.; Arranz, R. Bioinorganic transformations of liver iron deposits observed by tissue magnetic characterisation in a rat model. J. Inorg. Biochem., 2006, 100(11), 1790-1799.
87. Kirchner, C.; Liedl, T.; Kudera, S.; Pellegrino, T.; Munoz Javier, A.; Gaub, H. E.; Stölzle, S.; Fertig, N.; Parak, W. J. Cytotoxicity of colloidal CdSe and CdSe/ZnS nanoparticles. Nano Lett., 2005, 5(2), 331-338.
88. Rosen, B. P. Bacterial resistance to heavy metals and metalloids. J. Biol. Inorg. Chem., 1996, 1(4), 273-277.
89. Moreau, J. W.; Weber, P. K.; Martin, M. C.; Gilbert, B.; Hutcheon, I. D.; Banfield, J. F. Extracellular Proteins Limit the Dispersal of Biogenic Nanoparticles. Science, 2007, 316(5831), 1600-1603.
90. Bazylinski, D. A.; Frankel, R. B. Magnetosome formation in prokaryotes. Nat. Rev. Microbiol., 2004, 2(3), 217-230.
91. Lang, C.; Schuler, D. Biogenic nanoparticles: Production, characterization, and application of bacterial magnetosomes. J. Phys. Condens. Matter, 2006, 18(38), S2815-S2828.
92. Shankar, S. S.; Rai, A.; Ankamwar, B.; Singh, A.; Ahmad, A.; Sastry, M. Biological synthesis of triangular gold nanoprisms. Nat. Mater., 2004, 3(7), 482-488.
93. Nune, S. K.; Chanda, N.; Shukla, R.; Katti, K.; Kulkarni, R. R.; Thilakavathy, S.; Mekapothula, S.; Kannan, R.; Katti, K. V. Green nanotechnology from tea: phytochemicals in tea as building blocks for production of biocompatible gold nanoparticles. J. Mater. Chem., 2009, 19, 2912-2920.
94. Dameron, C. T.; Reese, R. N.; Mehra, R. K.; Kortan, A. R.; Carroll, P. J.; Steigerwald, M. L.; Brus, L. E.; Winge, D. R. Biosynthesis of cadmium sulphide quantum semiconductor crystallites. Nature, 1989, 338(6216), 596-597.
95. Labrenz, M.; Druschel, G. K.; Thomsen-Ebert, T.; Gilbert, B.; Welch, S. A.; Kemner, K. M.; Logan, G. A.; Summons, R. E.; Stasio, G. D.; Bond, P. L.; Lai, B.; Kelly, S. D.; Banfield, J. F. Formation of Sphalerite (ZnS) Deposits in Natural Biofilms of Sulfate-Reducing Bacteria. Science, 2000, 290(5497), 1744-1747.
96. Kumar, S. A.; Ansary, A. A.; Ahmad, A.; Khan, M. Extracellular biosynthesis of CdSe quantum dots by the fungus, fusarium oxysporum. J. Biomed. Nanotechnol., 2007, 3, 190-194.
97. Alkilany, A. M.; Nagaria, P. K.; Hexel, C. R.; Shaw, T. J.; Murphy, C. J.; Wyatt, M. D. Cellular uptake and cytotoxicity of gold nanorods: molecular origin of cytotoxicity and surface effects. Small, 2009, 5(6), 701-708.
98. Leonov, A. P.; Zheng, J.; Clogston, J. D.; Stern, S. T.; Patri, A. K.; Wei, A. Detoxification of gold nanorods by treatment with polystyrenesulfonate. ACS Nano, 2008, 2(12), 2481-2488.
99. Bastús, N. G.; Casals, E.; Vazquez-Campos, S.; Puntes, V. Reactivity of engineered inorganic nanoparticles and carbon nanostructures in biological media. Nanotoxicology, 2008, 2(3), 99-112.